DRTX Key Stats
- Notable Analyst Rating Changes 03/06: (BIIB) (COG) (HA) Upgraded; (AUXL) (LOV) (ARTC) Downgraded Street Insider 03/06 10:34 ET
- Roth Capital Starts Durata Therapeutics (DRTX) at Buy Street Insider 03/06 08:11 ET
- Craig-Hallum Starts Durata Therapeutics (DRTX) at Buy Street Insider 03/06 08:10 ET
- Durata Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire 03/03 08:00 ET
- Nasdaq stocks posting largest percentage increases AP 02/28 18:03 ET
- Durata Therapeutics (DRTX) Jumps: Stock Rises 6.5% Yahoo 02/19 02:24 ET
- Durata Therapeutics to Present at the RBC Capital Markets' Global Healthcare Conference noodls 02/18 09:07 ET
- 3 Companies Facing FDA Approval: Chelsea, MannKind, and Durata Yahoo 02/14 12:17 ET
- Durata Therapeutics: Primed For Big Gains With March Advisory Committee Date Announced Yahoo 02/13 11:22 ET
- Antibiotic Companies To Cash In On In 2014 Yahoo 02/13 08:30 ET
DRTX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Durata Therapeutics is up 56.68% over the last year vs S&P 500 Total Return up 24.37%, Jazz Pharmaceuticals up 162.4%, and Celladon up N/A.
Balance Sheet View Statement
Pro Ratings for DRTX
Pro Strategies Featuring DRTX
Did Durata Therapeutics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: Illinois
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Durata Therapeutics Inc is a clinical development stage biopharmaceutical company. The Company develops and commercializes novel therapeutics for patients with infectious diseases and acute illnesses.